Q1 2025 Management View Jacqui Shea, President and CEO, highlighted that Inovio remains on track to submit its BLA for ...

Good afternoon, ladies and gentlemen, and welcome to the Inovio First Quarter 2025 Financial Results Conference Call. At this time all participants are in a listen-only mode. [Operator Instructions] ...

On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respirato ...

The National Institute of Allergy and Infectious Diseases (NIAID) plans to initiate phase 1 clinical trial of Capricor's ...

BLA's freedom struggle actions are part of coordinated attacks under Operation Herof 2.0 military exercise during which a total of 78 missions were carried out at 58 locations.

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, ...

Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today reported its business highlights ...

The BLA has claimed responsibility for a total of 71 "coordinated attacks" at more than 51 locations across Pakistan's Balochistan province as part of its 'Operation Herof' over the last few weeks.

The FDA will issue a decision on the BLA for RGX-121 by November, which if positive, could make it the first gene therapy for Hunter syndrome.

Discover REGENXBIO's Q1 2025 milestones, including FDA updates, pivotal trial progress, and commercial readiness for gene therapies addressing rare ...

Conflicting QSSD definitions from two federal agencies mean that CMS’ administrative authority on drug pricing and payment is ...